These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 190361)

  • 1. Chemotherapeutic trials on human malignant astrocytomas in organ culture.
    Saez RJ; Campbell RJ; Laws ER
    J Neurosurg; 1977 Mar; 46(3):320-7. PubMed ID: 190361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
    Levin VA; Crafts DC; Wilson CB; Schultz MJ; Boldrey EB; Enot KJ; Pischer TL; Seager M; Elashoff RM
    Cancer Treat Rep; 1976 Mar; 60(3):243-9. PubMed ID: 177210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
    Liau CT; Wei KC; Tseng CK; Jung SM
    Chang Gung Med J; 2005 Jan; 28(1):16-23. PubMed ID: 15804144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of mustoforan in management of malignant glioma].
    Kobiakov GL
    Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
    [No Abstract]   [Full Text] [Related]  

  • 5. Nitrosoureas: a review of experimental antitumor activity.
    Schabel FM
    Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
    Vitanovics D; Sipos L; Afra D
    Neoplasma; 2002; 49(5):342-5. PubMed ID: 12458335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful chemotherapy for recurrent malignant oligodendroglioma.
    Cairncross JG; Macdonald DR
    Ann Neurol; 1988 Apr; 23(4):360-4. PubMed ID: 3382171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro analysis of BCNU-sensitivity in human malignant gliomas. I. A model study with alkylating, cross-linking and carbamoylating agents in anaplastic astrocytomas of pediatric age.
    Gerosa MA; Rosenblum ML; Stevanoni G; Tommasi M; Della Corte V; Licata C; Bricolo A; Tridente G
    Acta Neurol Scand; 1985 Oct; 72(4):414-8. PubMed ID: 3002083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency of the radio-chemo-surgical. Treatment in cerebral astrocytomas.
    Constantinovici A; Cristescu AM
    Zentralbl Neurochir; 1989; 50(2):109-14. PubMed ID: 2560306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemoradiation for malignant brain tumors].
    Matsutani M
    Gan To Kagaku Ryoho; 1997 Nov; 24(14):2042-8. PubMed ID: 9388512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCNU solubility and toxicity in the treatment of malignant astrocytomas.
    Layton PB; Greenberg HS; Stetson PL; Ensminger WD; Gyves JW
    J Neurosurg; 1984 Jun; 60(6):1134-7. PubMed ID: 6726357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.
    Solero CL; Monfardini S; Brambilla C; Vaghi A; Valagussa P; Morello G; Bonadonna G
    Cancer Clin Trials; 1979; 2(1):43-8. PubMed ID: 229983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
    Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
    Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCNU treatment of astrocytomas: erratum.
    Layton PB
    J Neurosurg; 1984 Sep; 61(3):621. PubMed ID: 6747712
    [No Abstract]   [Full Text] [Related]  

  • 16. Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
    Jayawardena S; Sooriabalan D; Indulkar S; Kim HH; Matin A; Maini A
    Am J Ther; 2006; 13(5):458-9. PubMed ID: 16988542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy of cerebral tumours: data on malignant gliomas (author's transl)].
    Schiffer D; Giordana MT; Liboni W; Ravetti C; Soffietti R; Tarenzi L; Sannazzari GL; Negri GL
    Riv Patol Nerv Ment; 1978; 99(6):327-42. PubMed ID: 756619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrosoureas in the management of disseminated malignant melanoma.
    Ahmann DL
    Cancer Treat Rep; 1976 Jun; 60(6):747-51. PubMed ID: 782696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of neuroectodermal brain tumors.
    Shapiro WR
    Ann Neurol; 1982 Sep; 12(3):231-7. PubMed ID: 6753729
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
    Mulcahy RT; Siemann DW
    Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.